Dec 02, 2025 21:30
SONN - Sonnet BioTherapeutics Holdings, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 4.45 0.05 (1.14%) | --- | -0.01 (-0.31%) | -0.03 (-0.73%) | 0.0 (0.0%) | 0.22 (5.16%) | 0.0 (0.0%) | 0.19 (4.46%) |
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -0.89
- Diluted EPS:
- -0.89
- Basic P/E:
- -5.0572
- Diluted P/E:
- -5.0572
- RSI(14) 1m:
- 38.21
- VWAP:
- 4.46
- RVol:
Events
| Period | Kind | Movement | Occurred At |
|---|
Related News
Dec 02, 2025 14:17
Nov 19, 2025 17:29
Sep 19, 2025 13:00
Jul 19, 2025 14:21
Jul 18, 2025 21:32
Jul 14, 2025 23:49
Jul 14, 2025 22:54
Jul 14, 2025 10:00
Jul 14, 2025 10:00